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Switch from conventional to high-flux membrane reduces the risk of
carpal tunnel syndrome and mortality of hemodialysis patients. The use
of a high-flux membrane, which eliminates larger molecular weight solutes
with better biocompatibihty, has steadily increased since the discovery of
beta-2 microglohulin (j32m) amyloidosis in 1985. The long-term effects of
a dialyzer membrane on morbidity and mortality are not completely
understood. To examine the membrane effect as a factor of carpal tunnel
syndrome onset and mortality, multivariate Cox regression analysis with
time-dependent covariate was conducted on 819 patients from March
1968 to November 1994 at a single center. Two hundred and forty-eight of
the patients were either switched from the conventional to high-flux
membrane or treated only with a high-flux membrane. Fifty-one patients
underwent a CTS operation and 206 died. Membrane status (on high-flux
or on conventional) was considered as time-dependent covariate and risk
was adjusted for age, gender, type of renal disease and calendar year of
dialysis initiation. The relative risk of CTS was reduced to 0.503 (P < 0.05)
and mortality 0.613 (P < 0.05) by dialysis on the high-flux membrane,
compared to the conventional membrane. Serial measurements of 2m
indicated significantly lower ,m to persist in patients on the high-flux
membrane. The high-flux membrane decreased the risk of morbidity and
mortality substantially. Larger molecule elimination was shown important
not only for preventing j32m amyloidosis, but for prolonging survival of
dialysis patients as well.
By dialysis therapy, very long-term survival of end-stage renal
failure patients is possible, but frequently is attended with dis-
abling problems associated with beta-2 microglobulin (132m) amy-
loidosis [1, 2]. Dialysis with the high-flux membrane has found
increasing application in Japan since the recognition of f32m
amyloidosis as a specific complication of a chronic dialysis patient
in 1985 [3]. The high-flux membrane or high-performance mem-
brane removes larger molecular weight solutes, including J32m,
with better biocompatihility than the conventional unsubstituted
cellulose membrane. These advantages should ensure a lesser
incidence of p2m-amyloidosis and better life prognosis. However,
the long-term effects of the dialyzer membranes have yet to be
fully determined [4—121. Also, whether the membrane switch from
conventional to high-flux membrane actually alleviates dialysis-
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related amyloidosis or mortality has not been confirmed [101. This
study was conducted to examine the effects of high-flux membrane
for lessening the risk of the carpal tunnel syndrome (CTS), a
representative manifestation of 2m-amyloidosis, and mortality.
Risk assessment was made for a large number of patients using
Cox-proportional hazard model.
METHODS
Patients who began dialysis therapy at this hospital between
January 1968 and November 1994 were studied. We excluded
visiting patients. Only 819 patients participated and all had a
complete dialyzer history available; this included those who had
undergone hemodiafiltration or hemofiltration transiently, since
the purpose of the treatment was ,m removal. Characteristics of
the patients and blood purification methods are specified in
Tables 1 and 2. Mean age at hemodialysis initiation increased over
the 27 years of follow-up from 35.0 to 59.9 and diabetes patients
increased form 2.3 to 25.6%.
The indication for a high-flux membrane in this study was 2m
elimination with consequently less postdialysis 32m concentration
than predialysis. Accordingly, high-flux membrane materials were
polymethylmethacrylate (PMMA), polyacrylonitrile (PAN/AN69),
polysulfone (PS), cellulose-triacetate (CTA), and polyester-poly-
mer-alloy (PEPA).
Before November 1984, primarily the conventional cellulosic
membrane had been used. For the patients complicated with
dialysis arthropathy, the high-flux membrane was used and the
results arc reported elsewhere [131. Two years later when 2m was
found responsible for this type of amyloidosis, its use was started
at the beginning of dialysis and continued as much as possible
regardless of arthropathy. The number of patients on high-flux
membrane increased steadily to 224 (58%) of 386 patients treated
in 1994 (Fig. 1). No patient who had been placed on the high-flux
membrane subsequently returned to the conventional membrane.
Dialyzers were never reused. All patients underwent four to five
hours of hemodialysis three times weekly after seven to eight
hours of dialysis during 1968 to 1970.
Reverse osmosis was introduced in 1976 and was fully in use in
1981; the bicarbonate dialysate supplying system was put into use
in 1984, and volumetric controllers in 1978. Endotoxin-cut ultra-
filter was introduced in 1988 and a mean dialysate endotoxin at
the terminal console always remained less than 20 pg/mi [11.
Carpal tunnel syndrome (CTS) was considered to be present in
the case of decompression surgery. The indication for surgery was
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Number of patients 819
Sex ratio, M/F 525/294
Age at Onset of dialysis 50.2 17.3
Follow-up in years 5.8 6.4
(range) (0.1 —27.9)
First year dialysis
median 1982
range 1966—1994
Cause of renal failure
Non-DM 689
CGN 458
PCK 77
Nephrosclerosis 81
Others 73
DM 130
Table 2. Method of blood purification
HD on conventional membrane 571
Switch to high-flux membrane I 85U
HD on high-flux membrane 63
81 9
'Includes 28 cases treated temporarily by HF or HDF with high-flux
membrane
I
AT1f
1965 1970 1975 1980 1985 1990
N=34 N=154 N198 N=261 N=300
Year
Fig. 1. Frequency of patients using high flux membrane.
made by an orthopedic physician with no knowledge of the
detailed dialysis treatment, based on the intensity of clinical
symptoms and electronic measurement of motor nerve conduc-
tion velocity. Patients without histological evidence of 132m-
amyloid or those without roentographycal evidence of hone cyst
were excluded because of possible non-amyloidosis CTS. Two
female patients operated on at four and six years of dialysis
therapy were excluded.
Serum 2m was measured serially in a subgroup of patients
prior to and following the membrane switch. The membrane
switch was done irrespective of residual renal function. 2m levels
were mixed with or without residual renal function in both
membrane treatments. Reduction in f32m was determined as:
(Pre — Post)/Pre X 100 (%). Kt/V was calculated according to
Daugirdas's formula [14], averaged and compared for sequential
three years for the conventional and high-flux membranes.
Statistical analysis
The Cox proportional hazard model with a time-dependent
covariate was used to assess the effects of high-flux membrane
CTS surgery 51
during conventional membrane 28
during high-flux 23
Censored 251
Transferred to another hospital 311
Death 196
Renal transplantation 10
819, 4543 person-years
Table 4. Outcomes of death
Death 206
Cardiovascular 105
Infection 42
Malignancy 11
Others 17
Censored 289
Transferred to another hospital 314
Renal transplantation 10
with the computer program PHREG, SAS version 6.08. Dates of
the two end points, CTS surgery and death, were recorded. The
time from initiation of dialysis to the end point was considered
influenced by covariates of (1) patient age, (2) calendar year at
dialysis initiation, (3) gender, (4) cause of renal failure, diabetes
or non-diabetes and (5) membrane status. Membrane status was
time-dependent because many patients initially started dialysis on
conventional membrane and then switched to the high-flux mem-
brane (Appendix). This approach has ever been used for analysis
of heart transplant recipients 15j.
Patient death, transfer to other units, switching to peritoneal
dialysis or renal transplantation before CTS onset were regarded
as censored information as well as continual dialysis without CTS
surgery at the final observation date.
Some early cases were changed to high-flux membranes for the
appearance of CTS. It could be a significant bias to include them
as they were, because they would receive surgical operation very
shortly. To adjust this bias, we performed three approaches with,
(a) excluding such symptomatic cases, (b) including them as
carryover by counting the time after switchover to operation day
as conventional membrane, and (c) including them as censored
cases at the time they changed membranes.
The contribution of covariates for explaining dependent vari-
able was assessed by a two-tailed likelihood ratio test with P values
less than 0.05 considered to be significant. Mann-Whitney's U-test
and the chi-square test were used as needed. All data were
expressed as mean so.
RESULTS
The summarized proportion of high-flux membrane use was
PMMA 32.4%, CTA 28.6%, PAN/ANÔ9 17.2%, PS 16.7%, PEPA
3.4% and others 1.7%. The proportion of conventional membrane
use was unsubstituted cellulose membrane 77.4%, cellulose ace-
tate 19.9% and others 2.7%.
Data for outcomes of CTS surgery and death are indicated in
Tables 3 and 4 respectively. Specific causes of mortality are listed
in Table 5. Cardiovascular disease and infection incidence was
Table 1. Patient characteristics Table 3. Outcomes of CTS surgery
819, 4783 person-years
100
80
60
40
20
0
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Table 5. Mortality
Cardiovascular Infection Malignancy Others
Mortality expressed as percentage
of observed deaths
Total 57.8 20.4 5.3 16.5 (%)
during low-flux 63.7 22.2 4.1 9.9
during high-flux 60.0 20.0 11.4 8.6
Mortality expressed as number!
1000 patient-years
Total 26.2 9.2 2.4 7.5
during low-flux 30.2 10.5 1.9 4.7
during high-flux 22.4 7.5 4.3 3.2
Variable
Risk ratio (P value)
Analysis A Analysis B Analysis C
Membrane 0.646 (0.29) 0.500 (0.05)' 0.311 (0.01)a
Female 0.727 (0.34) 0.782 (0.42) 0.917 (0.82)
Diabetes 1.046 (0.97) 0.951 (0.96) 1.351 (0.78)
Age 1.065 (0.0001)a 1.064 (0.0001)a 1.081 (0.0001)'
Calendar year 0.991 (0.85) 0.999 (0.97) 1.009 (0.87)
slightly higher during conventional membrane use but did not
reach statistical significance.
Relative risks are shown in Table 6, as calculated by the
proportional hazard model with three different end points for
CTS surgery. The analysis (a) excluding symptomatic cases obvi-
ously has a strong bias in favor of the conventional membrane
because established CTS needs decompression surgery very
shortly. Actually, there were seven eases symptomatic of CTS who
used a conventional membrane for 13.7 2.0 years and under-
went an operation shortly after membrane switching, at 0.27 years
(3.3 months). Analysis (b), which dealt with this 0.27 years as
carryover, was more realistic than (c) because it included the
information of end point data (operation day). Therefore, analysis
(b) was considered the best to adjust for such symptomatic
switcher's bias, which revealed that membrane status and age at
the initiation of dialysis have a significant influence on the
incidence of CTS (Table 7). The high-flux membrane decreased
the risk of CTS to 0.503 (Fig. 2). In the mortality analysis,
membrane status, age, gender and cause of renal failure were
independent prognostic factors for survival (Table 8). High-flux
membrane decreased the risk of mortality to 0.613 (Fig. 3).
Changes in the mean predialysis serum 2m and reduction rate
are shown in Figures 4 and 5. In switched cases (N = 181),
predialysis 2m fell by 22% from 39.1 11.2 mg/liter before
switching to 30.5 7.2 mg/liter after switching. Enhanced removal
of 132m (averaged RR 40.2 21.4% after switching) continued for
seven years at most (Fig. 4). In non-switched cases, predialysis
f32m was 31% less in the initially high-flux started group (26.2
6.0 mg/liter, N = 49) than the low-flux started group (37.7 9.5
mg/liter, N = 308; Fig. 5). Mean Kt/V slightly increased following
membrane switch, 1.41 0.10 to 1.48 0.08 (N = 182,P < 0.01).
Table 7. Relative risk of each covariate for CTS (end point was CTS
operation)
Variable
.Risk
ratio
95%
Lower
CI
Upper
P value
ehi square
(1) Membrane 0.638 0.334 1.218 0.17
(2) Membrane 0.500 0.250 0.998 0.05
Female 0.782 0.427 1.432 0.42
Diabetes 0.951 0.122 7.394 0.96
Age 1.064 1.038 1.091 0.0001
Calendar year 0,999 0.913 1.093 0.97
(3) Membran&'
Ageb
0.503
1.062
0.263
1.039
0.964
1.086
0.03
0.0001
a 95% confidence intervals
b Significant covariates in best-fitted model
The sets of covariates included were: (1) membrane status alone, (2) all
the covariates and (3) selected covariates that were statistically significant
at 5%.
DISCUSSION
Since the late 1980s, the use of high-flux membranes has
increased steadily, and recently it has been made more porous and
biocompatible. Whether this membrane delays the onset of
amyloid deposition and improves survival are points of the
greatest concern. In spite of better permeability and biocompat-
ihility, the results for long-term use of high-flux membrane are
very few. Risk of p2m-associated morbidity and mortality was
Table 6. Relative risk for CTS calculated by three separate analyses
(end point is CTS operation)
Analysis A excluded symptomatic eases with CTS, N = 812; analysis B
dealt with them as a carryover, N = 819; and analysis C dealt with them
as censored, N = 819.
a Statistically significant
(a
a)
>
ci)
1.2
1.0
0.8
0.5
0.2
0.0
Conventional High-flux
Membrane status
P<0.05
Age Age+1
Age
P<0.001
Fig. 2. Significant covariates and relative risks for carpal tunnel syn-
drome.
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shown in this study to be influenced by use of the high-flux
membranes.
Most studies deal with short-term trials or are restricted to
certain membrane types such as PS, PMMA, or most often PAN
[4—7, 9, 11]. Whether results with PAN/AN69 are applicable for
assessment of other types of high-flux membranes is not known, in
this study, attention was directed to membrane permeability, with
special emphasis on 2m elimination. Results were obtained using
various types of high-flux membranes able to remove significant
2m.
A period of at least 10 years or more is necessary to reach the
primary f37m-related end point; however, proper membrane
choice for patients with disabling complications should be man-
datory at present. The Cox proportional hazard model was used to
exclude the effects of confounding factors. The ultrafiltration
controller, medication and ultrapure dialysate are suspected
determining factors, but they were not considered in the present
study for it was extremely difficult to operationally define such
factors. We dealt the conditions that could not be modifiable
except membrane status.
E
CM
20
E 40
a)
m 60
w ..
0 1 2 3 4 5 6 7 8 9 10
Time, years
Fig. 5. Time course of predialysis 132m and removal rate with conven-
tional and high flux membrane groups. Data are means 5D. Symbols in
upper graph are: (•) conventional (N = 308) and (El) high flux (N = 49)
membrane data; * < 0.001. Tn the lower graph, symbols are: (Li)
conventional and (El) high flux membrane data.
The membrane data from patients who changed membrane
type was considered to be a time-dependent covariate in Cox's
proportional hazard model [15, 161. To accurately evaluate a
time-dependent covariate, there must be no prior use of a
high-flux membrane by less risky patients so that the association
between membrane type and end points will not be over-rated. If
we observe CTS-presenting symptomatic patients without switch-
ing to the high-flux membrane, the high-flux membrane effect
would be found to be more preferable.
Only few comparisons have been made of the long-term effects
of various dialysis membranes on patient morbidity and mortality.
Charnard et al noted the CTS onset to be delayed in patients
exclusively dialyzed on the PANIAN69 membrane [4]. A retro-
spective case-control study comparing cellulosic membrane and
PAN dialysis results indicated an insignificant decrease in the
prevalence of arthropathy, joint pain and CTS in PAN [5]. van
Table 8. Relative risk for mortality of each covariate (end point was
death)
Variable
.Risk
ratio
95%
Lower
CI
____
Upper
P value
chi square
(1) Membrane 0.794 0.528 1.194 0.27
(2) Membrane 0.654 0.426 1.004 0.05
Female 0.656 0.489 0.880 0.005
Diabetes 1.977 1.403 2.786 0.0001
Age 1.080 1.067 1.093 0.0001
Calendar year 0.985 0.955 1.017 0.35
(3) Membrane5
Female5
0.613
0.652
0.409
0.486
0.919
0.874
0.02
0.004
Diabetes" 1.909 1.366 2.668 0.0002
Age" 1.077 1.065 1.089 0.0001
* * *
I I
—2—10 1 2 34 56 7 8 910
Years after switching membrane
95% confidence intervals
"Significant covariates in best-fitted-model
The sets of covariates included were: (1) membrane Status alone, (2) all
the covariates, and (3) selected covariates that were statistically significant
at 5%.
2.0
1.5
C,)I
1.0
>
a)
a) 0.5
Fig. 4. Time course of predialysis 132m and the removal rate in the
membrane-switched group (N = 181); data are means Symbols are:
(•) conventional membrane data; (LIJ) high-flux membrane data; (Li)
upward bars (minus) indicate an increase in 132m following the dialysis
session. *P < 0.001 vs. 0 year.
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Fig. 3. Significant covariates and relative risks for mortality.
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Ypersele de Strihou et a! observed that patients on PAN/AN69
membrane to be less likely to develop radiologically-determined
bone cysts than those on the cellulosic membrane [61, but survival
without CTS to be the same, which is at variance with the present
results. They maintain that CTS operation is a poor marker of
132m amyloidosis since (1) CTS occurs even in non-dialyzed
patients and thus non-amyloid-induced CTS is possible, and (2)
the criteria for surgery is not uniform. In the present study,
however, CTS operated patients without 132m were not included,
nor were there any patients from other hospitals (no center bias).
CTS operation was thus considered a significant marker for /32m
amyloidosis.
The present study confirms a lesser risk of mortality by the
high-flux membrane, as also noted by Hornberger et a! [16].
Follow-up time in the latter was rather short, but the relative risk
of mortality decreased to 0.24 with the high-flux membrane, and
the annual mortality was substantially less, that is, 7% compared
to 20% by the conventional cellulosic membrane. Chandran,
Liggett and Kirkpatrick observed a lower mortality rate in patients
on PAN/AN69 than would be expected from the U.S. Renal Data
System mortality project [8]. More recently, Hakim et al clearly
demonstrated that the relative risks of mortality with modified
cellulose or synthetic membranes are 20 to 25% lower than with
unsubstituted cellulose membrane, adjusting KtIV and regional
effects in a large number of patients [101.
In contrast to these results, there is a pessimistic view of
membrane effect. Bonomini et al specified membranes as cellulo-
sic or synthetic [17] and could found no significant difference in
long-term effects between them. Membrane classification and
maintenance predialysis f32m were in contrast to the present study.
The capacity for 13,m elimination, not membrane material, was
the basis for membrane classification in the current study. Thus,
our patients on high-flux membrane clearly showed lower predi-
alysis 132m than on the conventional membrane.
Predialysis f32m in some studies has been shown to remain
unchanged after a mid-term of high-flux dialysis, but the present
study indicated that a sustained decrease (22%) was basically the
same as that of Mrowka and Schiffi, who reported reduced 132m 20
to 35% for over six years with the PS membrane [18]. Locatelli et
al also demonstrated 16 to 23% decrease in predialysis 132m in
high-flux membrane hemodialysis or hemodiafiltration for 24
months [12]. /32m amyloidosis may possibly be caused by retention
of f32m over many years. 132m synthesis in dialysis patients takes
place essentially to the same extent as in normal control subjects
[19]. Sufficient f32m removal to counterbalance its generation
should thus avoid its further retention that would pose risk factor.
132m itself expresses biological activity that is particularly strong
on becoming an advanced glycation end product [20]. 132m should
thus be removed and maintained at low level. Even moderate
reduction (22 to 31%) in maintenance predialysis /32m compared
to conventional membrane is suggested by the present study to
reduce the risk of f32m-associated morbidity.
Nutritional improvement [21], less frequent infection, less
nephrotoxic effect, plasma lipoprotein profile improvement [22],
and less acute intradialytic deleterious effects compared to bioin-
compatible membranes may be possible explanations for the
present results [23]. However, the specific reasons for these results
cannot be ascertained from this study. The cause for mortality
with either membrane appeared to be essentially the same. KtIV
is a very important indicator of the adequacy of dialysis that is
related to morbidity and mortality [24]. In this study, KtIV
increased with the high-flux membrane, but only slightly. Desir-
ably high Kt/V was achieved prior to use, possibly due to the
considerable clearance of small molecules by either membrane
and unchanged time of dialysis. Kt!V increment would thus have
contributed less to the present result.
As this is a retrospective and uncontrolled study, caution is
needed in interpreting the results. The results, however, were
obtained in a single center, so the data collection and treatment
policy are uniform and without "center effect"; there are very long
term-follow-ups and serial 132m measurements. It is important to
underline the fact that the beneficial effect was at least associated
with continually reduced 132m due mainly to flux and some extent
to by biocompatibility [25]. The elimination of larger toxins such
as 132m should also be considered not only for preventing J32m
amyloidosis, but also prolonging the dialysis patient survival. The
results should provide a motivation to prospectively test the
importance of flux as well as the biocompatibility of dialyzer
membranes.
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APPENDIX
Abbreviations
Abbreviations used in this paper include: CTS, carpal tunnel syndrome;
132m, 13-2 microglobulin; PMMA, polymethylmethaciylate; PAN/AN69,
polyacrylonitrile; PS, polysulfone; CTA, cellulose-triacetate; PEPA, poly-
ester-polymer-alloy.
Time dependent covariate
There are certain Situations in which the proportional hazard assump-
tion do not hold in the Cox model. That means that hazard ratios or the
value of covariate change across time. In this study, membrane status (Z),
was treated as a segmented time-dependent covariate as shown below.
T3
V=T3-T1j
High-flux
start
In this model, Ti is the time of hemodialysis initiation, T2, the time of the
end point or censored time and T3, the time of change to the high-flux
membrane. W represents the term on conventional membrane. Z can be
defined as 0 if time is less than W or 1 if time equal to or greater than W.
Accordingly, Z is a time-dependent covariate.
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